Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.

Article Details

Citation

Stein EA, Heimann KW

Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.

S Afr Med J. 1975 Jul 19;49(31):1252-6.

PubMed ID
168650 [ View in PubMed
]
Abstract

Fifty-seven patients, mean age 26 years, suffering from familial hyperbetalipoproteinaemia (Fredrickson type lla and llb), were treated on a low cholesterol, modified polyunsaturated fat diet for a period of 6-12 weeks prior to the introduction of drug therapy. No significant reduction in the serum levels of total cholesterol, low density lipoprotein (LDL) cholesterol or triglyceride was found. Fifty patients were then treated with colestipol for 6 weeks; total and LDL cholesterol decreased by 23%, but triglyceride levels were unaffected. During the following 6 weeks, placebo was administered, and total and LDL cholesterol returned to pretreatment levels. The patients were then randomly allocated into two groups of 16. The first group continued with clofibrate therapy, while the second group received cholestyramine. In the clofibrate group a reduction in total and LDL cholesterol of the order of 17% was noted, similar to cholestethat achieved in this group on colestipol. Triglyceride levels were 15% lower on clofibrate therapy than on colestipol. In the cholestyramine group, there was a 25% decrease in total and LDL cholesterol, compared with pretreatment levels. This reduction was similar to that found when colestipol was administered. Triglyceride values were significantly raised during cholestyramine therapy. Thirteen patients were then subjected to a 6-week period of combination therapy, either clofibrate or colestipol, or clofibrate and cholestyramine. Total and LDL cholesterol were reduced by 32% on combination therapy compared with 18% on colestipol and 23% on either clofibrate or cholestyramine alone. Furthermore, on combined therapy, triglyceride concentrations fell by 20% when compared with the levels found when colestipol, clofibrate or cholestyramine were administered on their own.

DrugBank Data that Cites this Article

Pharmaco-metabolomics
DrugDrug GroupsMetaboliteChangeDescription
CholestyramineApproved InvestigationalTotal cholesterol
decreased
Cholestyramine decreases the level of Total cholesterol in the blood
CholestyramineApproved InvestigationalTriglycerides
decreased
Cholestyramine decreases the level of Triglycerides in the blood
ColestipolApprovedTriglycerides
decreased
Colestipol decreases the level of Triglycerides in the blood
ColestipolApprovedTotal cholesterol
decreased
Colestipol decreases the level of Total cholesterol in the blood
ClofibrateApproved InvestigationalTriglycerides
decreased
Clofibrate decreases the level of Triglycerides in the blood
CholestyramineApproved InvestigationalLDL cholesterol
decreased
Cholestyramine decreases the level of LDL cholesterol in the blood
ClofibrateApproved InvestigationalLDL cholesterol
decreased
Clofibrate decreases the level of LDL cholesterol in the blood
CholestyramineApproved InvestigationalTriglycerides
increased
Cholestyramine increases the level of Triglycerides in the blood
ColestipolApprovedLDL cholesterol
decreased
Colestipol decreases the level of LDL cholesterol in the blood
ClofibrateApproved InvestigationalTotal cholesterol
decreased
Clofibrate decreases the level of Total cholesterol in the blood